Clinical Trial News and Research

RSS

Combo therapy restores T cell numbers in HIV-infected individuals

White blood cells known as CD4+ T cells are the main target of HIV.

16 Mar 2009

Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes

A study to determine if patients with type 2 diabetes can benefit from a combination of autologous (patient self-donated) stem cell infusions (ASC) and hyperbaric (above the normal air pressure of ) oxygen treatment (HBO) before and after ASC has found "significant benefits" in terms of "improvements in glycemic control" along with "reduced insulin requirements."

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

BioCis Pharma starts trial of novel topical drug for dermatology

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.

12 Mar 2009

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.

12 Mar 2009

Shining light on diabetic retinopathy

A group of scientists in California is trying to develop a cheaper, less invasive way to spot the early stages of retinal damage from diabetic retinopathy, the leading cause of blindness in American adults, before it leads to blindness.

11 Mar 2009

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Screening for breast cancer risk in all postmenopausal women, using a combination of risk factors and breast density, can identify women at high risk of disease, according to systematic literature reviews and meta-analyses reported in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Study methods influence estimates of lead time and overdiagnosis in prostate cancer

In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Immune-based therapy approved in Europe for pediatric cancer patients

The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.

11 Mar 2009

Folic acid appears to double risk for prostate cancer

A study led by researchers at the University of Southern California (USC) found that men who took a daily folic acid supplement of 1 mg daily had more than twice the risk of prostate cancer compared with men who took a placebo.

11 Mar 2009

A vaccine for multiple sclerosis

Apitope Technology Ltd is a biopharmaceutical company that specialises in developing treatments for allergy and autoimmune diseases.

11 Mar 2009

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009

Advances in stem cell research

Scientists at The University of Texas Health Science Center at Houston are on the forefront of stem cell research, developing novel therapies designed to generate heart cells, repair traumatic lung injuries, grow new bone and stanch the spread of cancer cells.

8 Mar 2009

Vaginal microbicide gel shows promise as HIV prevention method for women

A clinical trial involving more than 3,000 women in the U.S. and southern Africa demonstrates for the first time the promise of a vaginal microbicide gel for preventing HIV infection in women.

5 Mar 2009

Folic acid, B vitamins in Animi-3 may prevent vision loss

A new study by researchers at Harvard Medical School has found that combining essential B vitamins, including B6, B12, and folic acid, lower risk of developing age-related macular degeneration (AMD), one of the leading causes of vision loss among older Americans.

4 Mar 2009

Cordex Pharma files ATPace formulation patent

Cordex Pharma, Inc. has announced today that it has filed a formulation patent covering its lead product, ATPace.

4 Mar 2009

Regular moderate alcohol intake associated with greater bone mineral density

Researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University found associations were strongest for beer and wine and, importantly, BMD was significantly lower in men drinking more than two servings of liquor per day.

3 Mar 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Aerovance starts trial of Aerovant for uncontrolled asthma

Aerovance Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

3 Mar 2009